Switch studies: A review

HIV Medicine

Volumn 3, Issue 2, 2002, Pages 146-155

  Murphy, R L ^a   Smith, W J ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; EFAVIRENZ; LAMIVUDINE PLUS ZIDOVUDINE; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACUTE HEPATITIS; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CONTROLLED STUDY; DIARRHEA; DRUG HYPERSENSITIVITY; FOLLOW UP; GASTROINTESTINAL DISEASE; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPODYSTROPHY; LONG TERM CARE; METABOLIC DISORDER; METHODOLOGY; NEPHROTOXICITY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RASH; REVIEW; SYMPTOMATOLOGY; TREATMENT FAILURE;

DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; RANDOMIZED CONTROLLED TRIALS; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 0036258816     PISSN: 14642662     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-1293.2002.00102.x     Document Type: Review

References (40)

1. Antiretroviral therapy in adults: Updated recommendations of the International AIDS Society-USA Panel
2. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy
3. Reasons for discontinuation of protease inhibitor treatment: A clinical survey
4. Adherence to antiretroviral therapy (ART) among women in the HIV Epidemiology Research Study (HERS) and Women's Inter-Agency HIV Study (WIHS)
5. Highly active antiretroviral therapy (HAART) in the 'real world': Experiences in an inner-city community health center (CHC)
6. Early antiretroviral therapy: Rationale, protease inhibitor-sparing regimens and once daily dosing
7. Successful substitution of protease inhibitors with efavirenz (EFV) in patients with undetectable viral loads - A prospective, randomized, multicenter, open-label study (DMP 049)
8. The Maintavir Study, substitution of a non-nucleoside reverse transcriptase inhibitor (NNRTI) for a protease inhibitor (PI) in patients with undetectable plasma HIV-1 RNA: 18 months follow-up
9. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors
10. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: Contribution to protease inhibitor-related lipodystrophy syndrome
11. New-onset diabetes mellitus associated with use of protease inhibitor
12. Increase of atherogenic plasma profile in HIV-infected patients treated with protease inhibitor-containing regimens
13. Severe premature coronary artery disease with protease inhibitors
14. Osteopenia in a randomised, multicenter study of protease inhibitor substitution in patients with the lipodystrophy syndrome and well controlled HIV viremia
15. Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy
16. Adherence to antiretroviral therapy among HIV positive women
17. Highly active antiretroviral therapy in a large urban clinic: Risk factors for virologic failure and adverse drug reactions
18. ABT-378/ritonavir (ABT-378/r) in antiretroviral naive HIV + patients: 72 weeks
19. Impact of switching from protease inhibitors (PI) to nevirapine (NVP) or efavirenz (EFV) in patients with viral suppression
20. Substitution of a nonnucleoside reverse transcriptase inhibitor for a protease inhibitor in the treatment of patients with undetectable plasma human immunodeficiency virus type 1 RNA
21. Long-term efficacy and tolerance of switching the protease inhibitor for non-nucleoside reverse transcriptase inhibitors: A 52-week, multicenter, prospective study
22. Clinical, virological, and immunological benefit of switching the protease inhibitor (PI) by nevirapine (NVP) in HAART-experienced patients suffering lipodystrophy (LD): 36-week
23. Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy
24. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine
25. A prospective open label pilot trial of a maintenance nevirapine containing regimen in patients with undetectable viral loads on protease inhibitors for at least 6 months
26. Simplified maintenance therapy with NNRTI (nevirapine) in patients with long term suppression of HIV-1 RNA. First results of a cohort study
27. Switching from protease inhibitors to efavirenz does not improve clinical lipodystrophy and hyperlipidaemia in HIV-infected patients
28. An open randomized study on the replacement of HIV-1 protease inhibitors by efavirenz in chronically suppressed HIV-1-infected patients with lipodystrophy
29. Switching to efavirenz from protease inhibitor-based therapy does not improve insulin resistance after one year in HIV patients with lipodystrophy syndrome
30. One-year follow-up of HIV-infected children receiving combination therapy with indinavir, stavudine (d4T), and didanosine (ddI)
31. Adherence to antiretroviral medications in HIV-infected children. A collaborative approach with guidelines for care
32. Is simplification of haart safe in hiv-infected children? First pediatric switch study
33. Simplified maintenance therapy with abacavir + lamivudine + zidovudine in patients with HAART-induced long-term suppression of HIV-1 RNA
34. A novel use of abacavir to simplify therapy and reduce toxicity in PI experienced patients successfully treated with HAART: 48-week results (CNA30017)
35. Switching from PI to ABC improves insulin sensitivity and fasting lipids - 12-month follow-up
36. Use of Trizivir® (abacavir, lamivudine, zidouvidine) to simplify therapy in HAART-experienced subjects with long-term suppression of HIV-RNA. TRIZAL Study (AZL30002): 24-week results
37. Switching protease inhibitors to nevirapine (NVP), efavirenz (EFV) or abacavir (ABC): A randomized, multicenter, open-label, simplification trial
38. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy
39. Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: Preliminary results of the LIPOCO study